溴新斯的明(Neostigmine Bromide) - 药物靶点：ACHE_在研适应症：慢性胃炎，功能性便秘，排尿困难_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Neostigmine bromide (JAN/USP/INN)、Prostigmin

+ [2]

靶点

ACHE

作用方式

抑制剂、拮抗剂

作用机制

AChE抑制剂(乙酰胆碱酯酶抑制剂)、肌松拮抗剂

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [2]

在研适应症

慢性胃炎功能性便秘排尿困难+ [1]

非在研适应症-

原研机构-

在研机构

Kyowa Pharmaceutical Industry Co., Ltd.

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (1956-04-14),

慢性胃炎功能性便秘排尿困难+ [1]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C12H19BrN2O2

InChIKeyLULNWZDBKTWDGK-UHFFFAOYSA-M

CAS号114-80-7

查看全部结构式(2)

关联

52

项与溴新斯的明相关的临床试验

NCT06685705

/ Not yet recruiting临床4期IIT

Comparative Study Between Intrathecal Magnesium Sulfate, Neostigmine and Fentanyl As Adjuvant for Bubivacaine in Postoperative Analgesia in Lower Abdominal Surgeries

Lower abdominal surgeries often result in severe pain, which in turn can cause rapid and shallow breathing, retention of secretions and poor patient compliance. Justifiably, apart from the fear for the surgery outcome, patients are concerned mainly with postoperative pain. If treated inadequately, acute pain can have serious consequences for patient health mainly with postoperative complications, prolonged recovery and increased length of hospital stay. Higher levels of postoperative pain and pain distress are associated with increased morbidity, poorer functional recovery, and reduced quality of life.
Aim of the study To compare the duration, quality of analgesia, and side effects between intrathecal Magnesium sulfate, neostigmine and fentanyl as adjuvant for bubivacaine as postoperative analgesia in lower abdominal surgeries

开始日期2024-12-01

申办/合作机构

Assiut University

CTRI/2023/07/055054

/ Completed临床4期IIT

Effect of neostigmine on attenuation of proinflammatory cytokines secretion when given as an adjunctive therapy in septic shock: A Randomized controlled trial - NIL

开始日期2023-07-20

申办/合作机构

All India Institute of Medical Sciences

PACTR202304565008785

/ RecruitingN/AIIT

Intramuscular Neostigmine and Postoperative Urinary Retention After Spinal Anesthesia for knee Arthroscopy, a Prospective Randomized Controlled Study

开始日期2023-04-15

申办/合作机构

Mansoura University

100 项与溴新斯的明相关的临床结果

登录后查看更多信息

100 项与溴新斯的明相关的转化医学

登录后查看更多信息

100 项与溴新斯的明相关的专利（医药）

登录后查看更多信息

6,444

项与溴新斯的明相关的文献（医药）

2025-05-01·Dyes and Pigments

Rational design of fast-responding and highly selective fluorescent probes for detecting and imaging acetylcholinesterase homeostatic changes in Alzheimer's disease

作者: Shen, Jiawen ; Zhang, Chenrun ; Shao, Yiwen ; Zhu, Hai-Liang ; Ullah, Inam

Alzheimer′s disease (AD) is a progressive amnestic cognitive deteriorating neurodegenerative disease.Acetylcholinesterase (AChE) has a very high catalytic hydrolysis efficiency, which can rapidly hydrolyze acetylcholine into choline, playing a critical role in regulating the nervous system.Therefore, we designed and synthesized a fluorescent probe capable of quant. detecting AChE called ACP.Most strikingly, an extremely low detection limit of 0.341U/mL is far superior to those of many probes.The approach of utilizing ACP enabled us to swiftly identify and track real-time alterations in intracellular AChE levels.Addnl., our study marks the pioneering use of ACP in effectively detecting an increase in AChE expression in C. elegans and mice models of Alzheimer′s disease (AD).In conclusion, this study provides a new tool for quant. detecting AChE levels and shows great potential for application in AChE-related studies.

2025-05-01·Anesthesia & Analgesia

Risk of Acute Complications with Rocuronium versus Cisatracurium in Patients with Chronic Kidney Disease: A Propensity-Matched Study

Article

作者: DeShazo, Sterling J. ; Kinsky, Michael P. ; Arango, Daniel ; Gomez, Jonathon I. ; Georgakis, Nikolas A.

BACKGROUND:Neuromuscular blocking agents (NMBAs) play an integral role in modern anesthesia by facilitating endotracheal tube placement, assisting with mechanical ventilation, and creating optimal surgical conditions. However, NMBAs can have deleterious side effects. The purpose of this study was to retrospectively analyze acute complications of 2 pharmacodynamically similar but pharmacokinetically different NMBAs and their respective reversal agents.METHODS:The global research network database, TriNetX, was used to evaluate deidentified patient information from 63 health care organizations. Cohort A was defined as patients aged 18 to 80 years who had chronic kidney disease (CKD) and were administered rocuronium with sugammadex. Cohort B was defined as patients aged 18 to 80 years who had CKD and were administered cisatracurium with neostigmine. Cohorts were propensity matched for age at event, ethnicity, race, sex, and relevant confounding pathologies. All outcomes besides mortality were analyzed from the same day to 1 week after administration of the indexed drug. Mortality was analyzed from the same day to thirty days after administration of the indexed drug.RESULTS:A total of 95,740 patients with CKD-administered rocuronium with sugammadex were matched with 10,708 patients with CKD-administered cisatracurium with neostigmine. Patients administered rocuronium with sugammadex had a significantly higher associated risk of respiratory failure (risk ratios [RR], 1.98, confidence interval [CI], 1.71–2.29, P < .0001), acute respiratory distress (RR, 2.70, CI, 1.31–5.58, P = .0052), hypertensive crisis (RR, 1.85, CI, 1.37–2.49, P < .0001), heart failure (RR, 1.14, CI, 1.06–1.23, P = .0004), pleural effusion (RR, 1.30, CI, 1.14–1.49, P < .0001), and 30-day mortality (RR, 1.31, CI, 1.10–1.56, P = .0021).CONCLUSIONS:From 2003 to 2023, patients who were administered rocuronium plus sugammadex were at a significantly higher risk for acute cardiovascular and pulmonary complications when compared to patients who were administered cisatracurium plus neostigmine.

2025-05-01·Anesthesia & Analgesia

Rocuronium-Sugammadex Versus Cisatracurium-Neostigmine in Kidney Disease: Making Sense of Surprising Results

Article

作者: Dutton, Richard P.

100 项与溴新斯的明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00995	溴新斯的明	S01EB06 N07AA01	DBSALT001191

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性胃炎	日本	Kyowa Pharmaceutical Industry Co., Ltd.	1956-04-14
功能性便秘	日本	Kyowa Pharmaceutical Industry Co., Ltd.	1956-04-14
排尿困难	日本	Kyowa Pharmaceutical Industry Co., Ltd.	1956-04-14
重症肌无力	日本	Kyowa Pharmaceutical Industry Co., Ltd.	1956-04-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02909439 (CTgov)	临床4期	神经肌肉阻滞逆转	80	Neostigmine (Neostigmine)	淵築繭選範齋鬱淵齋艱(鑰築觸範廠鹽襯鬱壓襯) = 艱願憲夢艱選憲鬱積鬱蓋壓齋糧衊觸憲範築築 (淵觸鹽淵艱願餘蓋膚積, 醖齋鑰膚齋築艱衊鑰鹹 ~ 鹹鏇淵鹽網獵醖鏇膚遞) 更多	-	2020-05-22
				Sugammadex (Sugammadex)	淵築繭選範齋鬱淵齋艱(鑰築觸範廠鹽襯鬱壓襯) = 鑰繭顧壓膚鬱鑰壓壓夢蓋壓齋糧衊觸憲範築築 (淵觸鹽淵艱願餘蓋膚積, 網淵鏇糧膚餘構廠獵憲 ~ 築繭範艱憲積醖廠簾鹽) 更多
NCT01962298 (SUDIA, CTgov)	临床3期	呼吸系统疾病 \| 肌肉疲劳 \| 肌肉无力	75	placebo+Single rocuronium dose (Single Rocuronium Dose - Placebo)	鏇選築衊鬱積鑰醖積構(網膚範願淵繭鏇襯衊廠) = 醖齋構廠觸鏇鏇鬱製簾觸壓憲網醖夢鬱範夢鑰 (壓顧構憲廠蓋窪膚製鬱, 願鏇構餘夢積醖願窪膚 ~ 衊蓋醖艱淵夢壓構衊窪) 更多	-	2018-10-24
				sugammadex 2mg/kg+Single rocuronium dose (Single Rocuronium Dose - Sugammadex)	鏇選築衊鬱積鑰醖積構(網膚範願淵繭鏇襯衊廠) = 選網憲遞襯鬱鹽顧簾網觸壓憲網醖夢鬱範夢鑰 (壓顧構憲廠蓋窪膚製鬱, 襯蓋醖鏇襯齋夢餘繭遞 ~ 範襯繭構選夢淵糧鏇築) 更多